Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 9/20 | 0.61 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.61 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.61 |
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7138426 | 0.98 | GNAO1 (0.65) | GNAO1GNAI3GNAI1NCF1KCNH2 | |
| SCHEMBL7133353 | 0.98 | GNAO1 (0.65) | GNAO1GNAI3GNAI1NCF1KCNH2 | |
| SCHEMBL10442381 | 0.98 | GNAO1 (0.65) | GNAO1GNAI3GNAI1NCF1KCNH2 | |
| SCHEMBL7130155 | 0.98 | GNAO1 (0.65) | GNAO1GNAI3GNAI1NCF1KCNH2 | |
| SCHEMBL7133428 | 0.98 | GNAO1 (0.65) | GNAO1GNAI3GNAI1NCF1KCNH2 | |
| Hydrochloric Acid SCHEMBL10442919 | 0.96 | GNAO1 (0.68) | GNAO1GNAI3GNAI1NCF1KCNH2 | |
| SCHEMBL2007745 | 0.94 | NCF1 (0.56) | GNAO1GNAI3GNAI1NCF1KCNH2 | |
| Hydrochloric Acid SCHEMBL6181139 | 0.92 | GNAO1 (0.56) | GNAO1GNAI3GNAI1NCF1KCNH2 | |
| SCHEMBL5119116 | 0.89 | GNAO1 (0.53) | GNAO1GNAI3GNAI1NCF1KCNH2 | |
| SCHEMBL1540650 | 0.85 | NCF1 (0.60) | GNAO1GNAI3GNAI1NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506901-B2 | 1-(9H-Carbazol-4-yloxy)-3-((1-(7-trifluoromethyl-quinolin-4-yl) -piperidin-4-lmethyl)-amino)-propan-2-ol, for example; treating diabetes, urinary continence, atherosclerosis, gastrointestinal disorders, glaucoma | WYETH | 2003-01-14 | — | — | US | disclosed |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-28 | — | — | US | disclosed |
| WO-2002006255-A2 | HYDROXY-(PIPERIDIN-4-YL-METHYLAMINO)-ALKYL BETA-3 ADRENERGIC RECEPTOR ANTAGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB2 | GNAO1 328/4885GNAI3 342/4885GNAI1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.